New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in transplant settings, drug options in decompe cirrhosis, and drug options in end-stage renal disease

Current Opinion in Organ Transplantation

Volumn 20, Issue 3, 2015, Pages 235-241

  Kwo, Paul Y ^a   Badshah, Maaz B ^b  

^a Department of Medicine   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Decompensated cirrhosis; Direct acting antiviral agents; End stage renal disease; Hepatitis C; Liver cirrhosis; Liver transplant

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; BOCEPREVIR; CYCLOSPORINE; DACLATASVIR; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; EVEROLIMUS; LEDIPASVIR PLUS SOFOSBUVIR; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PARITAPREVIR; SIMEPREVIR; SIROLIMUS; SOFOSBUVIR; TACROLIMUS; TELAPREVIR;

CHILD PUGH SCORE; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; DRUG METABOLISM; DRUG SAFETY; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG INTERACTION; HEPACIVIRUS; LIVER CIRRHOSIS; METABOLISM;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPACIVIRUS; HEPATITIS C; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS; LIVER TRANSPLANTATION;

EID: 84939793048     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000198     Document Type: Review

References (36)

1. Armstrong GL, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Inter Med 2006; 144:705–714.
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13:2436–2441.
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558–567.
4. Singal AK, et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95:755–760.
5. Lau JYN, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Inter Med 1996; 124:868–876.
6. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15:41–63.
7. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35–S46.
8. Gaetano JN. Benefit–risk assessment of new and emerging treatments for & hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf 2014; 6:37–45.
9. Bacon BR, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207–1217.
10. McHutchison JG, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580–593.
11. Poordad F, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195–1206.
12. Kwo PY, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705–716.
13. Kiser JJ, et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55:1620–1628.
14. Adiwijaya B., et al. Effect of mild and moderate hepatic impairment on telaprevir pharmacokinetics. In: 6th International Workshop on Clinical Pharmacology of HCV Therapy; 22–23 June 2011.
15. Izquierdo L, et al. Simeprevir for the treatment of hepatitis C virus infection. & Pharmacogenomics Per Med 2014; 7:241–249. Reviews pharmacokinetics of simeprevir.
16. You DM, Pockros PJ. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother 2013; 14:2581–2589.
17. Fridell RA, et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011; 85:7312–7320.
18. Belda O, Targett-Adams P. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res 2012; 170:1–14.
19. Lee C, et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A nonstructural viral protein. Virology 2011; 414:10–18.
20. Gao M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96–100.
21. Poole RM. Daclatasvirþ asunaprevir: first global approval. Drugs 2014; & 74:1559–1571. Discusses the important aspects of pharmacokinetics and metabolism of this regimen.
22. Fontana R, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13:1601–1605.
23. German P YJ, West S, et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir/sofosbuvir fixed dose combination tablet [Abstract P_15]. In: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. 19–21 May 2014.
24. Gentile I, et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV & infection. Expert Opin Investig Drugs 2014; 23:561–571.. Highlights some key pharmacokinetics of LDV.
25. Abbvie Corporation. Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) Prescribing Information. North Chicago, IL; December 2014.
26. Khatri A, Gaultier I, Menon R, et al. Pharmacokinetics and safety of co-administered ABT-450 plus ritonavir (ABT 450/r), ABT-267 and ABT-333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate and severe hepatic impairment. [Abstract 758]. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 9–13 November 2012; Boston. Hepatology vol. 56.
27. Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis 2010; 30:333–347.
28. Koch U, Narjes F. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect Disord Drug Targets 2006; 6:31–41.
29. Wagner F, et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients. Hepatology 2011; 54: 50–59.
30. Beaulieu PL. Nonnucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs 2007; 8:614–634.
31. Larrey D, et al. Rapid and strong antiviral activity of the nonnucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 2012; 57:39–46.
32. Kirby B, Gordi T, Symonds W, et al. Population pharmacokinetics of sofosbuvir and Its major metabolite (GS-331007) in healthy and HCV-Infected adult subjects. [Abstract]. In: 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 1–4 November 2013; Washington, DC, USA. Hepatology vol. 58.
33. Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. [Abstract 1101]. In: 47th Annual Meeting of the European Association for the Study of the Liver (EASL); 18–22 April 2012; Barcelona, Spain.
34. Charlton M, et al. Sofosbuvir and ribavirin for treatment of compensated && recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148:108–117. Discusses the efficacy of SOF along with ribavirin in liver transplant patients and demonstrates the no interactions with tacrolimus, mycophenolate, prednisone, cyclosporine, or azathioprine.
35. Kwo PY, et al. An interferon-free antiviral regimen for HCV after liver trans- && plantation. N Engl J Med 2014; 371:2375–2382. Describes why tacrolimus should be dosed weekly with the paritaprevir, ombitasvir, and dasabuvir with ribavirin regimen for genotype 1 hepatitis C in the post-transplant setting.
36. Werner CR, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18:1464–1470.